,
Startin, Carla M. https://orcid.org/0000-0001-9261-9924
Ashton, Nicholas J.
Hamburg, Sarah
Hithersay, Rosalyn
Wiseman, Frances K.
Mok, Kin Y.
Hardy, John
Lleó, Alberto
Lovestone, Simon
Parnetti, Lucilla
Zetterberg, Henrik
Hye, Abdul
Strydom, André
Funding for this research was provided by:
Wellcome Trust (098330/Z/12/Z)
UCL ARUK network
Article History
Received: 28 August 2018
Accepted: 21 February 2019
First Online: 21 March 2019
Ethics approval and consent to participate
: For adults with DS, ethical approval was obtained from the North West Wales Research Ethics Committee (13/WA/0194). Where individuals had capacity to consent for themselves we obtained written informed consent. Where individuals did not have capacity to consent a consultee was asked to approve the individual’s inclusion based on their knowledge of the individual and his/her wishes, in accordance with the UK Mental Capacity Act 2005.For adults with sAD and controls, ethical approval was obtained from the regional ethics committee. Plasma and CSF samples were routinely collected in all subjects undergoing a diagnostic work-up for suspected neurodegenerative diseases, with informed written consent obtained for their use in research from patients or their representatives.
: Not applicable.
: HZ has served at scientific advisory boards for Eli Lilly, Roche Diagnostics and Wave, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.